首页> 外文OA文献 >141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

【2h】

141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

机译：141PD：Ceritinib在患者（PTS）中的全身和颅内疗效，用克里齐替尼（CRZ）预处理，ALK重新排列（ALK +）非小细胞肺癌（NSCLC）和基线脑转移（BM）：升降升降机Ascend-2试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
E. Felip; L. Crinò; D.-W. Kim; D.R. Spigel; M. Nishio; T. Mok; G. Scagliotti; D. Cesic; S. Sutradhar; A.T. Shaw;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 [J] . Crino Lucio, Ahn Myung-Ju, De Marinis Filippo, Journal of Clinical Oncology . 2016,第24期

机译：Ceritinib对先前接受化学疗法和Crizotinib治疗的ALK重排非小细胞肺癌患者的全身和颅内活性的多中心II期研究：ASCEND-2的结果
2. Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients [J] . Jacques Cadranel, Alexis B. Cortot, Hervé Lena, ERJ Open Research . 2018,第1期

机译：赛妥替尼在克唑替尼预处理的ALK +晚期非小细胞肺癌患者中的真实生活经验
3. Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1 [J] . Kim D., Mehra R., Tan D. S. W., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Ceritinib在晚期间变性再生性淋巴瘤激酶（ALK）重排（ALK plus）非小细胞肺癌（NSCLC）患者中的疗效和安全性：ASCEND-1的更新
4. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
5. BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL [O] . Alice Shaw, Ranee Mehra, Daniel S.W. Tan, 2014

机译：BM-32CERITINIB（LDK378）用于治疗ASCEND-1试验中发生了ALK变种（ALK +）非小细胞肺癌（NSCLC）和脑转移瘤（BM）的患者
6. BMET-13. WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK+) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND -3 [O] . Ranee Mehra, Enriqueta Felip, Daniel Shao-Weng Tan, 2016

机译：BMET-13。 Ceritinib在ALK抑制剂（ALKI）中的全身和颅内疗效 - 患有ALK重新排列（ALK +）NSCLC和基线脑转移（BM）的患者：Ascend-1和-3的结果

141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials

著录项

引文网络

相似文献

相关主题

期刊订阅